Showing results (51-60 of 59) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
Journal of Diabetes Investigation|November 21, 2025
Efficacy and safety of insulin degludec/insulin aspart biosimilar B01711 vs originator insulin degludec/insulin aspart in Chinese patients with type 2 diabetes inadequately controlled on basal or premixed insulin: A multicenter, randomized, open-label, phase 3 studyLeili Gao, Zhifeng Cheng, Guoqing Ma, et al.
British Journal of Pharmacology|July 14, 2022
Gene-dosage effect of Pfkfb3 on monocyte/macrophage biology in atherosclerosisShuai Guo, Anqi Li, Xiaodong Fu, et al.
Cardiovascular Research|April 16, 2024
Endothelial nucleotide-binding oligomerization domain-like receptor protein 3 inflammasome regulation in atherosclerosisShuai Guo, Litao Wang, Kaixiang Cao, et al.
The Journal of Pathology|January 14, 2023
Glycolysis and de novo fatty acid synthesis cooperatively regulate pathological vascular smooth muscle cell phenotypic switching and neointimal hyperplasiaKaixiang Cao, Tiejun Zhang, Zou Li, et al.
Medcomm|February 14, 2025
Endothelial monocarboxylate transporter 1 drives atherosclerosis via a lactate/NADH/CtBP-mediated transrepression pathwayZou Li, Shuai Guo, Kaixiang Cao, et al.
Diabetes Care|April 9, 2021
Efficacy and Safety of Mulberry Twig Alkaloids Tablet for the Treatment of Type 2 Diabetes: A Multicenter, Randomized, Double-Blind, Double-Dummy, and Parallel Controlled Clinical TrialLing Qu, Xiaochun Liang, Guoqing Tian, et al.
Current Medical Research and Opinion|April 28, 2020
Efficacy and safety of DBPR108 monotherapy in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled, phase II clinical trialWei Wang, Jun Yao, Xiaohui Guo, et al.
BMC Medicine|October 9, 2023
Fotagliptin monotherapy with alogliptin as an active comparator in patients with uncontrolled type 2 diabetes mellitus: a randomized, multicenter, double-blind, placebo-controlled, phase 3 trialMingtong Xu, Kan Sun, Wenjie Xu, et al.
Nature Medicine|May 13, 2022
Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trialWenying Yang, Dalong Zhu, Shenglian Gan, et al.
Pageof 6